Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Ascendis Pharma A/S Stock Price (Quote) NASDAQ:ASND
$97.01 ( 1.69% ) Monday, 23rd May 2022
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $61.58 | $109.21 | Monday, 23rd May 2022 ASND stock ended at $97.01. This is 1.69% more than the trading day before Friday, 20th May 2022. During the day the stock fluctuated 4.98% from a day low at $93.45 to a day high of $98.11. |
| 90 days | $61.58 | $126.79 | |
| 52 weeks | $61.58 | $178.71 |
Historical Ascendis Pharma A/S prices
| Date | Open | High | Low | Close | Volume |
| 2022-05-23 | $95.53 | $98.11 | $93.45 | $97.01 | 573 274 |
| 2022-05-20 | $92.72 | $95.63 | $90.02 | $95.40 | 420 579 |
| 2022-05-19 | $86.16 | $91.29 | $85.00 | $91.13 | 538 404 |
| 2022-05-18 | $87.42 | $89.44 | $85.34 | $86.00 | 425 734 |
| 2022-05-17 | $86.06 | $90.93 | $85.03 | $88.97 | 459 039 |
| 2022-05-16 | $83.12 | $85.45 | $82.62 | $84.73 | 661 757 |
| 2022-05-13 | $80.51 | $85.95 | $79.36 | $83.12 | 1 169 573 |
| 2022-05-12 | $65.00 | $81.18 | $61.58 | $80.01 | 3 394 475 |
| 2022-05-11 | $81.79 | $84.89 | $75.75 | $78.08 | 1 017 438 |
| 2022-05-10 | $82.44 | $87.35 | $79.43 | $82.64 | 846 782 |
| 2022-05-09 | $81.68 | $83.08 | $75.70 | $78.90 | 826 398 |
| 2022-05-06 | $90.06 | $91.57 | $82.20 | $83.08 | 903 521 |
| 2022-05-05 | $93.07 | $94.31 | $88.83 | $90.22 | 404 221 |
| 2022-05-04 | $91.93 | $94.60 | $88.07 | $94.22 | 568 718 |
| 2022-05-03 | $91.01 | $93.64 | $89.76 | $92.10 | 272 755 |
| 2022-05-02 | $90.82 | $95.76 | $89.76 | $91.05 | 488 516 |
| 2022-04-29 | $97.51 | $99.89 | $89.34 | $91.27 | 733 558 |
| 2022-04-28 | $104.91 | $105.22 | $97.60 | $98.50 | 954 023 |
| 2022-04-27 | $104.31 | $105.70 | $103.00 | $103.28 | 262 876 |
| 2022-04-26 | $107.21 | $107.89 | $102.19 | $103.22 | 566 829 |
| 2022-04-25 | $105.28 | $109.21 | $105.25 | $108.29 | 476 547 |
| 2022-04-22 | $106.33 | $108.10 | $104.80 | $105.92 | 304 100 |
| 2022-04-21 | $110.20 | $110.83 | $105.30 | $106.05 | 446 000 |
| 2022-04-20 | $110.13 | $110.80 | $108.11 | $109.59 | 167 700 |
| 2022-04-19 | $106.96 | $111.11 | $106.00 | $109.78 | 238 800 |
| 2022-04-18 | $112.75 | $112.75 | $105.93 | $107.15 | 943 200 |
| 2022-04-14 | $115.29 | $115.29 | $111.98 | $112.96 | 372 419 |
| 2022-04-13 | $109.69 | $115.52 | $107.94 | $115.52 | 352 336 |
| 2022-04-12 | $107.41 | $110.65 | $106.44 | $108.84 | 640 640 |
| 2022-04-11 | $110.75 | $110.87 | $105.06 | $106.34 | 316 303 |
| 2022-04-08 | $112.23 | $115.41 | $110.76 | $111.21 | 299 827 |
| 2022-04-07 | $117.40 | $119.94 | $111.26 | $114.28 | 512 400 |
| 2022-04-06 | $114.03 | $119.07 | $113.04 | $117.61 | 398 300 |
| 2022-04-05 | $117.36 | $120.34 | $114.87 | $115.73 | 363 300 |
| 2022-04-04 | $116.22 | $120.69 | $115.28 | $117.40 | 255 400 |
| 2022-04-01 | $117.76 | $119.68 | $114.04 | $115.92 | 476 689 |
| 2022-03-31 | $115.83 | $118.93 | $115.26 | $117.28 | 439 926 |
| 2022-03-30 | $119.15 | $123.03 | $114.81 | $116.14 | 296 733 |
| 2022-03-29 | $112.16 | $120.48 | $112.16 | $119.40 | 529 400 |
| 2022-03-28 | $116.99 | $116.99 | $107.00 | $111.35 | 479 200 |
| 2022-03-25 | $117.06 | $117.50 | $111.92 | $114.39 | 2 425 900 |
| 2022-03-24 | $111.72 | $122.01 | $107.00 | $116.73 | 1 869 300 |
| 2022-03-23 | $122.39 | $122.96 | $116.74 | $117.14 | 237 500 |
| 2022-03-22 | $110.86 | $125.88 | $110.86 | $123.34 | 450 436 |
| 2022-03-21 | $116.91 | $126.79 | $111.11 | $111.58 | 327 044 |
| 2022-03-18 | $118.49 | $121.04 | $116.90 | $117.44 | 500 348 |
| 2022-03-17 | $122.47 | $124.27 | $116.96 | $118.49 | 380 700 |
| 2022-03-16 | $110.28 | $123.44 | $110.28 | $122.93 | 714 200 |
| 2022-03-15 | $108.94 | $111.28 | $104.49 | $109.44 | 914 200 |
| 2022-03-14 | $112.00 | $113.00 | $96.97 | $102.64 | 1 712 900 |
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in children and adults to treat growth hormone deficiency (GHD) and other indications; and TransCon Treprostinil that has completed Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening d... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
